Skip to content

A randomized controlled trial of sacral epidural injection and selective intervertebral foraminal injection in the treatment of single-segment lumbar spinal stenosis

A randomized controlled trial of sacral epidural injection and selective intervertebral foraminal injection in the treatment of single-segment lumbar spinal stenosis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900028038
Enrollment
Unknown
Registered
2019-12-08
Start date
2020-01-01
Completion date
Unknown
Last updated
2019-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lumbar spinal stenosis

Interventions

Group 1:Epidural injection of the sacral canal
Group 2:Selective intervertebral foramen injection

Sponsors

Xinjiang Uygur Autonomous Region Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) MRI of the lumbar spine showed single-segment lumbar canal stenosis without other significant degenerative changes, prolapse or free tissues; (2) a history of recurrent intermittent claudication and limited independent walking distance; (3) patients who need to relieve their own pain; (4) patients who fail to respond to other non-surgical treatments; (5) patients requiring surgical intervention; (6) patients with pain that may have an inflammatory basis; (7) lower limb pain = 12.

Exclusion criteria

Exclusion criteria: (1) the patient is unable or unwilling to undergo the operation; (2) the contrast agent should not be used due to a known allergic reaction; (3) the patient has evidence of untreated local infection at the surgical site; (4) the patient cannot cooperate during the operation; (5) allergy to any drug to be used; (6) pregnancy; (7) use anticoagulant at the same time; (8) congenital or exogenous anatomical disorders that threaten the safety and success of the operation; (9) known systemic infections; (10) co-existing diseases causing significant respiratory or cardiovascular damage; (11) immunosuppression;

Design outcomes

Primary

MeasureTime frame
NRS;ODI;

Countries

China

Contacts

Public ContactWei Hu

Second Department of Spine, Xinjiang Uygur Autonomous Region Hospital of Traditional Chinese Medicine

realhuwei@163.com+86 18199848111

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 14, 2026